Sandoz Finalizes Acquisition of Just-Evotec Biologics EU SAS, Reinforcing Biosimilars Leadership
Strategic deal expands in-house development and manufacturing capacity, leveraging state-of-the-art continuous manufacturing technology.
(Basel, December 8, 2025) – Sandoz Group AG (SIX: SDZ/OTCQX: SDZNY), the global leader in affordable medicines, announced the successful completion of its acquisition of Just-Evotec Biologics EU SAS (JEB SAS) from Evotec SE. The transaction includes the Toulouse development and manufacturing site in France, along with an indefinite license to cutting-edge continuous-manufacturing technology for biosimilars.
This acquisition is fully consistent with Sandoz’s biosimilar strategy, boosting its in-house drug substance development and manufacturing capabilities and using continuous manufacturing to increase efficiency and scalability. The move strengthens Sandoz’s position to capitalize on the anticipated global biosimilars Loss of Exclusivity (LoE) market, which is projected to exceed USD 300 billion over the next decade.
Richard Saynor, CEO of Sandoz, stated that the acquisition is a pivotal step toward consolidating the company’s position as the undisputed leader in biosimilars, granting greater control over pipeline development and enhancing access to high-quality, affordable biologics globally.
Technology and Strategic Alignment
-
Continuous Manufacturing Technology: Sandoz secured an indefinite license to the proprietary, fully automated, high-throughput continuous-manufacturing platform. This technology represents a transformative advancement in biosimilar production, enhancing operational efficiency, ensuring flexibility, and enabling cost-effective scalability.
-
European Network: The acquisition complements existing investments in Slovenia, supporting Sandoz’s goal to build a robust, end-to-end in-house biosimilars network across Europe.
-
The Slovenian site will focus on large-scale fed-batch drug substance manufacturing.
-
The Toulouse site will specialize in small-scale continuous manufacturing, creating operational synergies.
-
The transaction aligns with Sandoz’s existing capital expenditure commitments and will not impact the company’s 2025 financial guidance. All JEB SAS employees officially joined Sandoz on December 8, 2025.
